Xxxx Xxxxxx, M. A., RPA – Project Manager
Xxxx Xxxxxx, M. A., RPA – Project Manager 4 Xxxxxx Xxxxxxxx, Ph.D., RPA – Principal Investigator 6 Xxxxxxx Xxxxxxxxx, M.A., RPA – Principal Investigator 7 Xxxxxx Xxxx, Ph.D., RPA – Principal Investigator 7 Xxxx Xxxxxxxxxx, Ph.D., RPA – Principal Investigator 8 Xxxx Xxxxx, M.A. – Geoarchaeologist 9 Xxxxxxx XxXxxxx, M.A. – Principal Investigator 9 Xxxxx Xxxx, Ph.D. – Principal Investigator 10 Xxxxxxxxxxx XxXxxxxx, M.S. – Architectural Historian 11 Xxxxxx Xxxxxxxxxx, M.S. – Architectural Historian 12 Xxxxxx Xxxxxx, M.A. – Historian 12 Relevant Project Experience 13 Far Western 13 JRP 16 Project Understanding and Approach 17 Quality Assurance/Quality Control 17 Scheduling 18 References 19 Disadvantaged Business Enterprises (DBE) Utilization Plan 19 Attachment A. Key Personnel Resumes. Attachment B. Sealed Cost Proposal (Separate File). Figure 1. Team Organizational Chart 5 Far Western Anthropological Research Group, Inc., (Far Western) is a cultural resources management firm specializing in prehistoric and geoarchaeological studies throughout California and the Great Basin. Founded in 1979, Far Western is led by its executive management team of seven archaeologists and one GIS specialist, each renowned in their respective fields and who take an active participation in all Company projects. Far Western works with a variety of federal, state, and local agencies and private entities. Known for its innovative solutions to unique, and often difficult, environmental compliance issues, Far Western provides the full range of cultural resources management services, including simple records searches/constraints assessments, inventory of small- and large-scale projects, more extensive site eligibility evaluations, and data recovery/mitigation excavations. Far Western provides the expertise of 37 Ph.D.- and M.A.-level archaeologists; a federally recognized Qualified paleontologist; a five-person geoarchaeological department, which has modeled buried site sensitivity for 80 percent of California; a GIS department with nine dedicated GIS analysts for all forms of project mapping; and a production team that focuses on quality control and staying on schedule. Far Western staff meet the requirements of the California Department of Transportation (Caltrans) Professionally Qualified Staff (PQS) for Principal Investigators and Lead Archaeological Surveyors, and US Secretary of Interior’s Standards for Archaeology. Far Western takes its responsibilities to the archaeological community at large ve...
Xxxx Xxxxxx, M. D., Ph.X., inventor, CEO, and Chairman of the Board of Directors of Pharmazz, said: “India's emergence as a hub for developing and introducing innovative medicines is a remarkable achievement. It reflects the country's growing capabilities in research and development within the pharmaceutical sector. It is a large step for Pharmazz to partner with Xx. Xxxxx'x, a leading global pharmaceutical company from India. For patients with hypovolemic shock, I believe Xx. Xxxxx'x is the best partner for Pharmazz to market Centhaquine, an innovative, first-in-class novel resuscitative agent, in India." Hypovolemic shock is a life-threatening and often a fatal condition1. Severe loss of blood or fluids due to traumatic haemorrhage, postpartum haemorrhage, gastrointestinal bleeding, post-surgical bleeding, diarrhoea or vomiting can cause hypovolemic shock, which may lead to multi-organ failure and death. India has a high prevalence of these conditions and high mortality due to these conditions2. Data from various Indian studies and registries suggests a mortality rate of around 10 to 15% in traumatic haemorrhages despite the existing standard of care3. This suggests a need for a novel resuscitative agent which can improve the existing standard of care. Centhaquine was approved in India by Drugs Controller General of India following a successful phase III clinical trial. The results of are published in a manuscript entitled "A Multicentric, Randomized, Controlled Ph III Study of Centhaquine (Lyfaquin®), as a Resuscitative Agent in Hypovolemic Shock Patients”. The manuscript is published in DRUGS and is available at: xxxxx://xxxx.xxxxxxxx.xxx/article/10.1007/s40265-021-01547-5 Pharmazz received permission from the U.S. Food and Drug Administration (FDA) to conduct a Phase III clinical trial of centhaquine in hypovolemic shock patients. It assesses the safety and efficacy of centhaquine in patients with hypovolemic shock. The Phase III randomized double-blind, placebo-controlled study will be conducted in 430 patients where patients will receive either an intravenous infusion of 0.01 mg/Kg of centhaquine or a placebo. All patients will receive the standard of care. A 28-day all-cause mortality is the primary endpoint. Currently, Centhaquine is also under development for septic shock. ………………………………………………………………………………….………………………………………………………………….
Xxxx Xxxxxx, M. This transcription was made from a recording of the voice of Xxxx Xxxxxx, M.D., and forwarded for signature by tele-dictation company. Date transcribed: 06/11/15
